Revolutionizing Cancer Therapy with CABs
BioAtla (bioatla.com) scores 70 out of 100 on Brand Analyzer, placing it in the Developing tier among Healthcare brands, in the 22nd percentile of 14285 Healthcare brands.
BioAtla is a San Diego-based biopharmaceutical company founded in 2007 that develops cancer therapeutics using its proprietary Conditionally Active Biologics (CAB) technology. This platform is designed to create antibody-based therapies that selectively activate within the tumor microenvironment, aiming to improve treatment efficacy while reducing toxicity compared to conventional cancer therapies. The company positions itself as an innovator in next-generation oncology treatment, serving oncologists, cancer patients, biopharmaceutical partners, investors, and the broader scientific community.
| Brand Name | BioAtla |
|---|---|
| Domain | bioatla.com |
| Industry | Healthcare |
| Founded | 2007 |
| Headquarters | San Diego |
| Main Competitors | CytomX Therapeutics, Adagene, Mersana Therapeutics, Seagen (84/100), Regeneron (92/100), Genentech (84/100) |
Moz Domain Authority 36/100 vs category average 41 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #1,173,569 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Revolutionizing cancer therapy with Conditionally Active Biologics™" (Meta description: 7 words. OG description present but brief) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 2 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, Instagram; no detected presence on X (Twitter), Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is BioAtla?", Claude could identify the brand as of October 2026. BioAtla is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer, using its proprietary Conditionally Active Biologic (CAB) technology to create antibodies that preferentially bind to targets in the acidic tumor microenvironment while sparin Best known for Its CAB (Conditionally Active Biologic) antibody platform designed to improve the safety and selectivity of cancer therapeutics.
When asked "Best brands similar to BioAtla?", Claude would recommend BioAtla as of October 2026. It's a notable name in oncology biotech with a distinctive antibody technology platform, so it would be relevant if discussing innovative cancer-focused biopharma companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
BioAtla's main competitors in Healthcare: Seagen (84/100), Regeneron (92/100), Genentech (84/100).
Sources: Brand Analyzer scan
BioAtla has limited AI-search visibility, scoring 36/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 49, recommendation 48). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: BioAtla official site
BioAtla was founded in 2007. BioAtla operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
BioAtla is headquartered in San Diego. BioAtla operates in the Healthcare category.
Sources: Wikidata
BioAtla scores 48/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: BioAtla official site
BioAtla is a biopharmaceutical company headquartered in San Diego, United States, founded in 2007. It focuses on developing novel cancer therapeutics using its proprietary Conditionally Active Biologics (CAB) technology, which aims to create treatments with an improved therapeutic index compared to conventional cancer therapies.
Sources: BioAtla official site
BioAtla develops cancer therapeutics based on its Conditionally Active Biologics (CAB) technology. This proprietary platform creates biologic drugs designed to selectively target the tumor microenvironment, with the goal of improving treatment efficacy while reducing toxicity relative to conventional cancer treatments.
Sources: BioAtla official site
BioAtla can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: BioAtla official site
BioAtla develops cancer therapeutics using its Conditionally Active Biologics (CAB) technology platform. These are biologic drug candidates engineered to selectively target the tumor microenvironment, intended to improve treatment efficacy while reducing toxicity compared to conventional cancer therapies.
Sources: BioAtla official site
BioAtla is known for its proprietary Conditionally Active Biologics (CAB) platform, a technology designed to produce cancer therapeutics that selectively activate within the tumor microenvironment, offering a potentially improved therapeutic index over traditional cancer treatments.
Sources: BioAtla official site
BioAtla's work is relevant to oncologists, cancer patients, biopharmaceutical partners, investors, and the broader scientific community involved in advancing cancer treatment research and development.
Sources: BioAtla official site
BioAtla scores 36/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
BioAtla has a weak AI-visibility profile at 36/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is trust (49/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #1,173,569 (Tranco) and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data and a low Moz Domain Authority of 36/100. In a live check, Claude could already identify BioAtla from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to BioAtla: Bigfoot Biomedical (70/100), Board of Editors in the Life Sciences (BELS) (70/100), BioCircuit Technologies (70/100), Biologics Consulting (70/100).
A step up - brands to learn from: ZT Corporate (71/100), Zorgnet-Icuro (71/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.